InvestSMART

Lumos Diagnostics Holdings Limited (ASX: LDX) - Announcements

- Current share price for LDX : $0.100

ASX company news and announcements for Lumos Diagnostics Holdings Limited (LDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Lumos Diagnostics Holdings Limited (LDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Lumos Diagnostics Holdings Limited (LDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Lumos Diagnostics Holdings Limited (LDX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$94 Operational Update and Accelerated Entitlement Offer 6 Jun 2022 3:01PM $0.255 $0.100 fallen by 60.78%
$94 Trading Halt 2 Jun 2022 9:43AM $0.255 $0.100 fallen by 60.78%
$94 Pause in Trading 2 Jun 2022 9:15AM $0.255 $0.100 fallen by 60.78%
$94 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2022 9:37AM $0.310 $0.100 fallen by 67.74%
$94 Operational Review & Management Reorganisation 11 Apr 2022 9:26AM $0.325 $0.100 fallen by 69.23%
$94 Update - Notification of cessation of securities - LDX 5 Apr 2022 5:15PM $0.360 $0.100 fallen by 72.22%
$94 Notification of cessation of securities - LDX 1 Apr 2022 1:01PM $0.380 $0.100 fallen by 73.68%
$94 Notification regarding unquoted securities - LDX 1 Apr 2022 12:59PM $0.380 $0.100 fallen by 73.68%
$94 Change in substantial holding 14 Mar 2022 2:45PM $0.390 $0.100 fallen by 74.36%
$94 Change in substantial holding 1 Mar 2022 5:08PM $0.460 $0.100 fallen by 78.26%
$94 FebriDx Update - Brazil Market Authorisation & New Study 28 Feb 2022 8:27AM $0.590 $0.100 fallen by 83.05%
$94 FY2022 Half Year Update 28 Feb 2022 8:22AM $0.590 $0.100 fallen by 83.05%
$94 Lumos Diagnostics FY22 First Half Year Results 28 Feb 2022 8:20AM $0.590 $0.100 fallen by 83.05%
$94 Appendix 4D and Half Year Report 28 Feb 2022 8:10AM $0.590 $0.100 fallen by 83.05%
$94 Appointment of Chief Financial Officer 16 Feb 2022 9:59AM $0.850 $0.100 fallen by 88.24%
$94 Final Director's Interest Notice 11 Feb 2022 12:07PM $0.895 $0.100 fallen by 88.83%
$94 Change To Lumos Board 11 Feb 2022 12:03PM $0.895 $0.100 fallen by 88.83%
$94 Release of Shares from Escrow 11 Feb 2022 10:33AM $0.900 $0.100 fallen by 88.89%
$94 Application for quotation of securities - LDX 9 Feb 2022 2:02PM $0.985 $0.100 fallen by 89.85%
$94 Victorian Government Intent for Lumos Manufacturing Hub 2 Feb 2022 11:26AM $1.015 $0.100 fallen by 90.15%
$94 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2022 8:44AM $0.950 $0.100 fallen by 89.47%
$94 Change in Reporting Currency 31 Jan 2022 8:42AM $0.950 $0.100 fallen by 89.47%
$94 Notification of cessation of securities - LDX 12 Jan 2022 4:32PM $0.995 $0.100 fallen by 89.95%
$94 Over 100 Pharmacies in Liverpool UK Launch FebriDx Service 12 Jan 2022 9:47AM $0.995 $0.100 fallen by 89.95%
$94 Change in substantial holding 24 Dec 2021 1:06PM $0.700 $0.100 fallen by 85.71%

451 - 475 of 544 results

Page 19 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.